Taking Retinal Imaging Beyond Ophthalmology
Interview with identifeye HEALTH CEO Vicky Demas

Key Learnings From Vicky's Experience
Don’t get seduced by technical concepts when evaluating medtech ideas. It’s critical to identify problems truly worth solving — that also have a reasonable market size. Assess the unmet need and determine if you're genuinely passionate about addressing it. Vicky explains that while market size matters, long-term value comes from scalable solutions that fit within existing workflows.
For prototypes: test early and test often. Vicky is a big believer in getting your product into testing environments as soon as possible — even before it's fully functional. This is critical because user testing reveals unexpected behaviors and preferences that can't be anticipated in the lab — and it will help you refine your product iteratively while maintaining focus on core functionality.
Fundraising during market downturns is challenging, but not impossible if you hone in on factors within your control. When external funding conditions tighten, focus on creating demonstrable value and communicating a clear path to success. Present milestones in concrete terms that investors can easily understand. You can position yourself for success by maintaining relationships rather than scrambling when capital is needed.
The human retina contains a wealth of health information beyond just eye conditions. It's this insight that drives identifeye HEALTH's vision to create individualized treatment and care plans through accessible retinal imaging.
"We're leveraging AI and automation to make retinal imaging simpler, really bring it to the masses," says Vicky Demas, CEO of identifeye HEALTH. "Our thesis is creating a tool that supports personalized, preventative healthcare."
The company is starting with diabetic retinopathy, the leading cause of blindness in working-age adults. Despite established screening recommendations and reimbursement coverage, compliance remains low primarily due to accessibility barriers. Most patients currently need specialized ophthalmology referrals, which can create delays that lead to preventable vision loss.
identifeye's system combines AI analysis with consumer-inspired design to transform a specialized procedure into an accessible screening tool. The company aims to deploy its technology in primary care offices, integrated delivery networks, and potentially retail pharmacies — locations where most patients already receive routine care.
"The focus is trying to place devices closer to patients," Vicky explains. "We've built the device in a way that is super easy to use," she adds, noting that identifeye applies consumer product development principles to create intuitive medical devices — an approach that's uncommon in diagnostics.
With product development complete, identifeye is now transferring designs to manufacturing and preparing for market entry. Their initial product will be the camera system, with autonomous AI screening capability planned as a future software update.
Guest
CEO of Identifeye HEALTH
Vicky is the CEO of identifeye HEALTH (formerly Tesseract Health), where she leads the company's efforts to democratize access to retinal imaging. Before joining identifeye HEALTH, Vicky led new product development at GRAIL, supporting the creation of the company's multi-cancer early detection test (Galleri). She was also a founding member of Google Life Sciences (later Verily) within Google [x], where she led teams focused on diagnostics, medical devices, and translational laboratory science. An engineer and scientist, Vicky holds over 20 patents and has authored numerous scientific publications across multiple disciplines.
Sponsor Message
We recently released the seventh volume of Medsider Mentors, which summarizes key learnings from the most popular Medsider interviews over the last six months.
We get it—keeping up with every Medsider interview isn’t easy. That’s why we created Medsider Mentors. These e-book volumes distill the best practices and insider secrets from top founders and CEOs, all in a downloadable, easy-to-digest format.
Check out the latest volume here. Premium members get free access to all past and future volumes, plus a treasure trove of other resources.
If you’re not a premium member yet, you should definitely consider signing up. We recently revamped Medsider with swanky new features, especially for our premium members. In addition to every volume of Medsider Mentors, you’ll get full access to our entire interview library, dating back to 2010.
You’ll also get Medsider Playbooks—curated guides packed with actionable insights on topics like fundraising, regulatory challenges, reimbursement strategies, and more.
And if you’re fundraising, don’t miss our exclusive investor database, featuring over 750 life science VCs, family offices, and angels. We’ve even created 3 custom packages to help you with your next fundraise.
Learn more by visiting Medsider Mentors.
Beyond Technical Innovation: Finding Problems Worth Solving
For Vicky, evaluating medtech concepts begins with identifying meaningful problems — not just focusing on technical potential.
"It's really about finding a problem that's worth solving and truly understanding it," she explains, emphasizing the need for personal investment. "Especially if you're thinking about leaving your full-time job to do something or invest a lot of energy, you better pick a problem you really care about because [entrepreneurship is] not a 9-5 job."
This problem-first approach requires analyzing several key factors, with market size being an important one. While Vicky acknowledges its significance, she cautions against making it the only metric.
"There has to be an unmet need because there have to be people that will help you drive adoption," she notes. "Yes, you can just find something so niche that even if you took over the whole entire space, you still don't generate enough revenue to get investors excited."
Devices that serve small patient populations aren’t necessarily doomed, Vicky notes. You just need to show cost savings in other ways — such as reduced hospital stays, fewer complications, or improved outcomes.
But in identifeye’s case, the diabetic retinopathy market presented sufficient scale while offering clear adoption pathways and reimbursement mechanisms.
Vicky emphasizes that entrepreneurs must evaluate how their solution fits into existing healthcare workflows, which are notoriously difficult to change.
"Trying to figure out if this can fit with the people you have, with the workflow you have in a particular healthcare setting," is crucial for adoption, she notes.
The evaluation process must also include clear differentiation and scalability assessment. For diagnostic platforms especially, Vicky stresses the importance of expandability.
"If someone says, 'Here, I have a new diagnostic tool,' you always want to think about, 'Can the platform do more things? Can you detect more stuff? How scalable is the business?'"
The retinal imaging platform identifeye is building has significant expansion potential beyond diabetic retinopathy into cardiovascular risk assessment and other systemic conditions, creating long-term value.
"When you are building value, the economics usually follow," she says. "But you do need to do that homework to actually reach it."
Test Early, Test Often, and Leverage Feedback for Better Medical Device Design
Frequent iterations and rapid testing are key. Vicky's engineering background shapes her methodical approach to product development, with a strong focus on getting prototypes into testing environments quickly — a practice she's implemented at identifeye HEALTH.
"We can sit in isolation in our beautiful lab and build something. But what's really important is to test that the device or the prototype is safe and then try to get feedback."
The identifeye team has conducted extensive usability testing and smaller clinical studies under Institution Review Board oversight. This approach has yielded valuable insights that wouldn't have emerged in controlled laboratory settings — and can be used to refine product development.
"If you were to compare the earlier versions of the system to where it is today from a behavioral perspective, we've learned a ton from all of the interesting things that a participant might do when you're putting them in front of one of the systems, or what are some of the preferences of the operators," Vicky notes.
Quick product testing that meets safety standards is critical, and Vicky emphasizes that testing doesn’t need to wait until your system is fully functional. In identifeye’s case, the team tested retinal imaging components separately, and this approach was instrumental for developing the "goggles" interface that resembles a virtual reality headset. Testing has led to refinements that today make the tech so intuitive that users are able to run the exam even before they’ve finished a product demo.
Vicky’s advice is to think "very opportunistically about what prototypes and workflows you need to have outlined to capture feedback."
Staying focused while incorporating user feedback is essential — and you can do that through disciplined feature prioritization, which means distinguishing between essential requirements and "desirements" to prevent scope creep.
Setting clear acceptance criteria for each development stage helps prevent feature creep, which can derail timelines and drain resources. Vicky recommends "being disciplined in what you say you will accomplish at this phase, knowing that you will always have a list of things you would really like to improve in the next iteration."

Fundraising During Difficult Market Conditions: Focus on Value Creation
Having navigated fundraising during the 2007-2008 economic downturn, Vicky applies those lessons to the current investment environment. Her core principle: distinguish between external market factors and internal company initiatives.
"Market conditions I have no control over, which means you need to focus on things you can control," she says. What can an entrepreneur control? Value creation and clearly demonstrating that to your investors.
Rather than treating fundraising as a periodic activity triggered by depleted resources, Vicky views it as continuous relationship-building supported by measurable progress.
"People are always fundraising," she notes, contrasting this approach with the common pattern of entrepreneurs frantically networking when capital is needed. "Show metrics that say, these are the things we're working on as a team, even when you have the funds and you're moving forward so that people can track your progress and credibility."
When raising capital during constrained funding environments, she recommends focusing on concrete milestones that investors can easily grasp: completing a prototype, transferring design to manufacturing, conducting validation studies, or achieving initial revenue.
"Fundraise for things that people understand," Vicky advises. "It's easy for someone to understand, 'We're going to finish building a prototype, we're going to transfer design to manufacturing, we're going to run a clinical study for validation.' Concrete things."
Beyond fundraising mechanics, Vicky emphasizes building a support network of advisors and mentors. "It is so important to surround yourself with the right people, both in terms of who you bring as your team, but then also having the right network of advisors, mentors, eventually champions, helping you with connections."
Up Next — Looking Beyond the Eye
While identifeye HEALTH is currently focused on diabetic retinopathy screening, the company envisions a broader role in preventive medicine. The platform leverages what Vicky calls "a window to the body and health" — the retina's unique position as a source of biomarkers for cardiovascular risk, neurological conditions, and other systemic diseases.
The company’s strategic entry into the market through diabetic retinopathy delivers immediate clinical value while laying the groundwork for future applications. This focused approach enables identifeye to gather meaningful data from patients who frequently present with the very conditions the company aims to address next.
Sponsor Message
After raising over $40M from corporate venture and cardiovascular key opinion leaders, FastWave Medical has progressed rapidly in the development of its next-generation intravascular lithotripsy (IVL) systems for complex calcific disease.
The market size for IVL is over $9 billion and the only player in the space was recently acquired for over $13 billion. So naturally, there’s a lot of investor interest in FastWave.
Given the continued demand to invest in FastWave, their team has opened up an investor waitlist for anyone interested in potentially owning a piece of the company.
The last time the company opened up an private placement, it closed nearly $20 million in less than a month. So if you’re interested in investing in one of the hottest cardiovascular startups, opt into their investor waitlist here.
You May Like These Articles
Medsider Premium
Become a premium member and unlock access to exclusive Medsider benefits.